Search Results

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced the publication of its positive Measles and Rubella (MR) Phase 1/2 trial data in The Lancet Medical Journal.

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, announced the appointment of global public health pioneer, Dr. Seth Berkley, as scientific advisor to the CEO.

Micron Solutions, Inc., through its wholly-owned subsidiary, Micron Products, Inc. announced the Board’s approval of a proposal to effect a 1-for-1,000 reverse stock split of the Company’s Common Stock, followed immediately by a 1,000 to 1 forward stock split for the Company’s Common Stock, which Stock Splits will be enacted through the filing of amendments to the Company’s Certificate of Incorporation with the Secretary of State of the State of Delaware.

Micron Biomedical announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines.